Drug Profile
HMR 2091
Latest Information Update: 04 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Antiasthmatics
- Mechanism of Action Neurokinin 1 antagonists; Neurokinin 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 07 Jun 2000 Preclinical development for Asthma in USA (PO)